Match!
Ruth Plummer
Newcastle University
PharmacokineticsCancerPathologyCancer researchMedicine
228Publications
30H-index
4,031Citations
What is this?
Publications 239
Newest
#1Debashis Sarker ('KCL': King's College London)H-Index: 18
#1Debashis SarkerH-Index: 1
Last. Jeff EvansH-Index: 8
view all 36 authors...
Purpose: Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master regulator of hepatic and myeloid functions and multiple oncogenic processes. MTL-CEBPA is a first-in-class small activating RNA oligonucleotide drug which up-regulates C/EBP-α. Experimental Design: We conducted a phase I, open label, dose escalation trial of MTL-CEBPA in adults with advanced HCC with cirrhosis, or resulting from non-alcoholic steatohepatitis (NASH) or with liver metastases. Patients rec...
Source
#1Antoine Hollebecque (Institut Gustave Roussy)H-Index: 28
#1A. HollebecqueH-Index: 7
view all 20 authors...
Source
#1Rosie McNeillis (Newcastle upon Tyne Hospitals NHS Foundation Trust)
#2Alastair Greystoke (Newcastle University)H-Index: 17
Last. Ann Bowron (Newcastle upon Tyne Hospitals NHS Foundation Trust)
view all 12 authors...
A 47-year-old man with metastatic melanoma presented with refractory hyperlactaemic acidosis following the first dose of the mono-carboxylase transporter 1 inhibitor AZD3965 within a “first time in man” clinical trial. The mechanism of the agent and the temporal relationship suggested that this event was potentially drug related and recruitment was suspended. However, urinary metabolomics showed extensive abnormalities even prior to drug administration, leading to investigations for an underlyin...
Source
#1Laura Stuart (Newcastle University)H-Index: 1
#2Beth Lambourne (Newcastle upon Tyne Hospitals NHS Foundation Trust)H-Index: 1
Last. Jessica K. Dyson (Newcastle University)H-Index: 15
view all 7 authors...
Programmed cell death protein 1 receptor (PD-1) is a cell surface protein involved in immune response regulation. Pembrolizumab is a monoclonal antibody against PD-1 and used to treat patients with stage IV and III melanoma.(1) Immune-related hepatotoxicity is reported in 2-10% of patients(2) with case reports of vanishing bile duct syndrome(3), subacute biliary injury and immune cholangitis.(4).
1 CitationsSource
#1Reinhard Dummer (UZH: University of Zurich)H-Index: 98
#2A. Guminksi (USYD: University of Sydney)H-Index: 1
Last. Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 14
view all 17 authors...
1 CitationsSource
#1Dirk SchadendorfH-Index: 95
#2Paolo A. AsciertoH-Index: 61
Last. Paul C. NathanH-Index: 36
view all 28 authors...
Abstract Background Limited data are available on nivolumab in challenging subgroups with advanced melanoma. We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials. Patients and methods In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3 mg/kg, every 2 weeks for up to 2 years. The primary objective was incidence of grade ≥...
3 CitationsSource
#1Paul D. Nathan (NU: Northwood University)H-Index: 27
#1Paul Nathan (NU: Northwood University)H-Index: 15
Last. Joseph J. Sacco (University of Liverpool)H-Index: 7
view all 20 authors...
Source
#1Debashis Sarker ('KCL': King's College London)H-Index: 18
#2Ruth Plummer (Newcastle University)H-Index: 30
Last. Nagy A. Habib (Imperial College London)H-Index: 43
view all 12 authors...
Abstract Background MTL-CEBPA is a first-in-class small activating RNA (saRNA) oligonucleotide which specifically up-regulates the myeloid cell master regulator, C/EBP-α (CCAAT/enhancer-binding protein alpha). Methods We conducted a phase I, 3 + 3 dose escalation and dose expansion trial of MTL-CEBPA in adults with HCC or secondary liver cancer. Patients received intravenous MTL-CEBPA at 28-160 mg/m2 for 3 weeks either QW, BIW at d1 and d2, BIW at d1 and d3, or TIW at d1, d2, and d3 followed by ...
Source
#2Melissa Lynne Johnson (Sarah Cannon Research Institute)H-Index: 12
Last. M Barve
view all 20 authors...
Source
#1Mark P SaundersH-Index: 31
#2J. S. Graham (Beatson West of Scotland Cancer Centre)H-Index: 1
Last. D. J. KerrH-Index: 6
view all 9 authors...
Source
12345678910